RDEA3170

DRUG3 trials

Sponsors

AstraZeneca, Ardea Biosciences, Inc.

Conditions

GoutGout and Asymptomatic HyperuricemiaGout and Hyperuricemia

Phase 1

Mild, Moderate and Severe Renal Impairment Study

CompletedNCT02219516

Ardea Biosciences, Inc.Gout

Start: 2014-08-01End: 2016-05-13Updated: 2017-04-25

A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients

CompletedNCT02317861

AstraZenecaGout and Asymptomatic Hyperuricemia

Start: 2014-12-31End: 2015-06-30Updated: 2015-06-12

Phase 2

Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

CompletedNCT02078219

AstraZenecaGout and Hyperuricemia

Start: 2014-01-05End: 2015-03-13Updated: 2019-09-24

Related Papers

Higher Febuxostat Exposure Observed in Asian Compared with Caucasian Subjects Independent of Bodyweight.

2020-09-195 citations

Safety and efficacy of verinurad, a selective URAT1 inhibitor, for the treatment of patients with gout and/or asymptomatic hyperuricemia in the United States and Japan: Findings from two phase II trials

Modern Rheumatology2018-10-1850 citations

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.

2018-08-016 citations

Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study

Lara D. Veeken2018-04-1232 citations